Your browser doesn't support javascript.
loading
Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries.
de Jager, Vincent D; Timens, Wim; Bayle, Arnaud; Botling, Johan; Brcic, Luka; Büttner, Reinhard; Fernandes, Maria Gabriela O; Havel, Libor; Hochmair, Maximilian J; Hofman, Paul; Janssens, Annelies; Johansson, Mikael; van Kempen, Léon; Kern, Izidor; Lopez-Rios, Fernando; Lüchtenborg, Margreet; Machado, José Carlos; Mohorcic, Katja; Paz-Ares, Luis; Popat, Sanjay; Ryska, Ales; Taniere, Phillipe; Wolf, Jürgen; Schuuring, Ed; van der Wekken, Anthonie J.
Afiliación
  • de Jager VD; Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Timens W; Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Bayle A; Oncostat U1018, Inserm, Paris-Saclay University, Gustave Roussy, Villejuif, France.
  • Botling J; Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden.
  • Brcic L; Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria.
  • Büttner R; Institute of Medical Genetics and Applied Genomics, University of Tuebingen, Tuebingen, Germany.
  • Fernandes MGO; Pulmonology Department, Centro Hospitalar Universitário de São João, Porto, Portugal.
  • Havel L; Charles University and Thomayer Hospital, Prague, Czech Republic.
  • Hochmair MJ; Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria.
  • Hofman P; Department of Respiratory and Critical Care Medicine, Klinik Floridsdorf, Vienna Healthcare Group, Vienna, Austria.
  • Janssens A; IHU RespirERA, FHU OncoAge, Nice University Hospital, Côte d'Azur University, Nice, France.
  • Johansson M; Department of Oncology, University Hospital Antwerp, University of Antwerp, Edegem, Belgium.
  • van Kempen L; Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden.
  • Kern I; Department of Pathology, University Hospital Antwerp, University of Antwerp, Edegem, Belgium.
  • Lopez-Rios F; Laboratory for Cytology and Pathology, University Clinic Golnik, Golnik, Slovenia.
  • Lüchtenborg M; Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Research Institute Hospital 12 de Octubre (i+12), Ciberonc, Madrid, Spain.
  • Machado JC; National Disease Registration Service, NHS England, London, United Kingdom.
  • Mohorcic K; Centre for Cancer, Society & Public Health, King's College London, London, United Kingdom.
  • Paz-Ares L; Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal.
  • Popat S; Faculty of Medicine of the University of Porto, Institute for Research and Innovation in Health (i3S), Porto, Portugal.
  • Ryska A; University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.
  • Taniere P; Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, H12O-CNIO Lung Cancer Clinical Research Unit, Research Institute Hospital 12 de Octubre (i+12)/Spanish National Cancer Research Center (CNIO), Ciberonc, Madrid, Spain.
  • Wolf J; Lung Unit, Royal Marsden NHS Trust, London, United Kingdom.
  • Schuuring E; The Fingerland Department of Pathology, Charles University Medical Faculty and University Hospital, Czech Republic.
  • van der Wekken AJ; Department of Histopathology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
Lancet Reg Health Eur ; 38: 100838, 2024 Mar.
Article en En | MEDLINE | ID: mdl-38476742
ABSTRACT
In the past two decades, the treatment of metastatic non-small cell lung cancer (NSCLC), has undergone significant changes due to the introduction of targeted therapies and immunotherapy. These advancements have led to the need for predictive molecular tests to identify patients eligible for targeted therapy. This review provides an overview of the development and current application of targeted therapies and predictive biomarker testing in European patients with advanced stage NSCLC. Using data from eleven European countries, we conclude that recommendations for predictive testing are incorporated in national guidelines across Europe, although there are differences in their comprehensiveness. Moreover, the availability of recently EMA-approved targeted therapies varies between European countries. Unfortunately, routine assessment of national/regional molecular testing rates is limited. As a result, it remains uncertain which proportion of patients with metastatic NSCLC in Europe receive adequate predictive biomarker testing. Lastly, Molecular Tumor Boards (MTBs) for discussion of molecular test results are widely implemented, but national guidelines for their composition and functioning are lacking. The establishment of MTB guidelines can provide a framework for interpreting rare or complex mutations, facilitating appropriate treatment decision-making, and ensuring quality control.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Lancet Reg Health Eur Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Lancet Reg Health Eur Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido